TYPE 2 HEPATORENAL SYNDROME (Type2 HRS)
Safety and Efficacy of Terlipressin and Noradrenaline and Predictive Factors of Response in Type 2 HRS
About this trial
This is an interventional treatment trial for Safety and Efficacy of Terlipressin and Noradrenaline and Predictive Factors of Response in Type 2 HRS focused on measuring noradrenaline terlipressin type 2 HRS
Eligibility Criteria
Inclusion Criteria:
- Cirrhosis with ascites with serum creatinine more than 1.5 mg/dl and less than 2.5 mg/dl
- Absence of shock, fluid losses and treatment with nephrotoxic drug
- No improvement in renal function following diuretic withdrawal and plasma volume expansion
- No ultrasound evidence of renal parenchymal disease or obstructive uropathy 5.Absence of proteinuria more than 500 mg/24 hour
Exclusion Criteria:
- Patients with history of coronary artery disease
- Cardiomyopathy
- Ventricular arrhythmia
- Obstructive arterial disease of limbs -
Sites / Locations
- Postgraduate Institute of Medical Education and Research Chandigarh
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Terlipressin and Type-2 HRS
Noradrenaline and Type-2 HRS
Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour.
Patients in group B received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/hour, designed to achieve an increase in mean arterial pressure (MAP) of at least 10mmHg or an increase in 4-h urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 hour in steps of 0.5 mg/hour, up to the maximum dose of 3 mg/hour